| RNAi inhibition of alpha-ENaC expression |
2023-8-21 |
2023-9-07 |
|
| Targeting ligands for therapeutic compounds |
2023-5-17 |
2023-6-08 |
|
| Program, method, and information processing apparatus |
2023-5-15 |
2023-6-29 |
|
| α-1 ANTITRYPSIN (AAT) RNAi AGENTS, COMPOSITIONS INCLUDING AAT RNAi AGENTS, AND … |
2023-4-05 |
2023-6-01 |
|
| Integrin ligands and uses thereof |
2023-4-03 |
2023-5-25 |
|
| RNAi Agents and Compositions for Inhibiting Expression of Apolipoprotein C-III … |
2023-3-28 |
2023-5-25 |
|
| Methods for reducing z–aat protein levels |
2023-3-28 |
2023-4-17 |
|
| Organic compositions for treating EPAS1-related diseases |
2023-3-23 |
2023-5-16 |
|
| Subcutaneous delivery of rnai agents for inhibiting expression of receptor for … |
2023-3-21 |
2023-9-28 |
|
| RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And … |
2023-3-09 |
2023-8-24 |
|
| Skeletal muscle delivery platforms and methods of use thereof |
2023-3-03 |
2023-8-24 |
|
| Lipid conjugates for the delivery of therapeutic agents |
2023-3-03 |
2023-7-20 |
|
| RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 ( … |
2023-2-27 |
2023-4-13 |
|
| Rnai agents for inhibiting expression of coronavirus (cov) viral genomes, … |
2023-2-02 |
2023-8-10 |
|
| Compositions and methods for inhibiting gene expression of LPA |
2022-12-05 |
2023-2-02 |
|
| Compositions and methods for inhibition of factor xii gene expression |
2022-12-02 |
2023-3-14 |
|
| RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), … |
2022-10-28 |
2023-4-27 |
|
| Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), … |
2022-10-21 |
2023-4-27 |
|
| RNAi inhibition of α-ENaC expression |
2022-10-07 |
2022-12-20 |
|
| Arni agents to inhibit the expression of pnpla3, pharmaceutical compositions … |
2022-9-26 |
2022-10-31 |
|
| iRNA agents for infection caused by hepatitis b virus (divisional application … |
2022-9-13 |
2023-3-03 |
|
| Compositions and methods for inhibiting gene expression of Hepatitis B virus |
2022-7-20 |
2022-8-18 |
|
| RNAi agents for Hepatitis B virus infection |
2022-7-18 |
2022-10-06 |
|
| RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS |
2022-6-15 |
2022-11-17 |
|
| Program, method, and information processing apparatus |
2022-6-09 |
2022-11-25 |
|
| Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
2022-6-08 |
2023-1-05 |
|
| RNA INTERFERENCE AGENT (iRNA) ANTITRIPSIN (AAT) AND COMPOSITION THAT INCLUDES … |
2022-5-31 |
2023-8-30 |
|
| Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions … |
2022-5-27 |
2023-4-01 |
|
| Compositions and methods for inhibiting gene expression of factor Xll |
2022-5-12 |
2022-6-02 |
|
| Organic compositions to treat KRAS-related diseases |
2022-5-04 |
2022-5-26 |
|
| RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and … |
2022-4-28 |
2023-1-19 |
|
| Rnai agents for inhibiting expression of receptor for advanced glycation end- … |
2022-4-08 |
2023-2-01 |
|
| Rnai agents for inhibiting expression of receptor for advanced glycation end- … |
2022-4-07 |
2022-10-13 |
|
| Rnai agents for inhibiting expression of receptor for advanced glycation end- … |
2022-4-07 |
2023-10-05 |
|
| Organic compositions to treat hsf1-related diseases |
2022-4-06 |
2022-12-01 |
|
| Organic compositions to treat HSF1-related diseases |
2022-3-16 |
2022-4-07 |
|
| 5'-cyclo-phosphonate modified nucleotides |
2022-2-17 |
2022-4-12 |
|
| Compositions and methods for inhibiting gene expression of Hif2alpha |
2022-2-10 |
2022-3-03 |
|
| Methods For The Treatment Of APOC3-Related Diseases And Disorders |
2022-2-03 |
2022-5-19 |
|
| Methods for the treatment of alpha-1 antitrypsin deficiency (aatd) |
2022-1-04 |
2022-4-08 |
|
| Targeting ligands |
2021-12-02 |
2022-2-16 |
|
| RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use |
2021-11-29 |
2022-3-24 |
|
| Alpha-v beta-6 integrin ligands and uses thereof |
2021-10-14 |
2022-1-27 |
|
| ORGANIC COMPOSITIONS FOR TREATING BETA-ENaC-RELATED DISEASES |
2021-10-07 |
2022-1-11 |
|
| Organic compositions to treat Beta-ENac-related diseases |
2021-10-04 |
2021-10-28 |
|
| Methods for reducing Z-AAT protein levels |
2021-9-14 |
2023-8-29 |
|
| METHODS FOR REDUCING Z-AAT PROTEIN LEVELS |
2021-9-14 |
2022-12-07 |
|
| RNAi AGENTS TO INHIBIT THE EXPRESSION OF DUX4, COMPOSITIONS OF SUCH AGENTS, AND … |
2021-9-10 |
2022-12-07 |
|
| LIPID CONJUGATES FOR THE TRANSPORT OF THERAPEUTIC AGENTS |
2021-9-10 |
2022-12-07 |
|
| RNAi agents for inhibiting DUX4 expression, compositions and methods of use |
2021-9-10 |
2023-9-22 |
|
| Skeletal muscle delivery platforms and methods of use |
2021-9-10 |
2022-3-17 |
|
| PLATFORMS FOR DRUG TRANSPORT INTO SKELETAL MUSCLE AND METHODS OF USE |
2021-9-10 |
2022-12-07 |
|
| Integrin targeting ligands and uses thereof |
2021-9-10 |
2023-4-06 |
|
| Skeletal muscle delivery platform and method of use |
2021-9-10 |
2023-7-25 |
|
| Rnai agents for hepatitis b virus infection |
2021-8-06 |
2021-12-23 |
|
| RNAi therapy for hepatitis B virus infection |
2021-7-09 |
2021-11-18 |
|
| Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions … |
2021-7-07 |
2021-8-31 |
|
| RNAi Agents to Inhibit the Expression of 17beta-HSD Type 13 (HSD17B13), … |
2021-4-19 |
2021-5-31 |
|
| LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING … |
2021-4-15 |
2022-7-13 |
|
| Integrin targeting ligands and uses thereof |
2020-10-23 |
2021-3-11 |
|
| Trialkyne linking agents and methods of use |
2020-8-12 |
2020-9-30 |
|
| Compositions and Methods for Inhibiting Expression of RRM2 Genes |
2020-4-13 |
2020-9-03 |
|
| RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION |
2020-2-07 |
2021-10-05 |
|
| RNAi AGENTS TO INHIBIT THE EXPRESSION OF HIF-2 a (EPAS1), COMPOSITIONS AND … |
2020-1-09 |
2021-8-25 |
|
| Integrin targeting ligands and uses thereof |
2019-10-27 |
2020-10-21 |
|
| RNAi AGENTS TO INHIBIT THE EXPRESSION OF 17b-HSD TYPE 13 (HSD17B13), … |
2019-9-19 |
2020-10-07 |
|
| Organic compositions to treat hsf1-related diseases |
2019-6-24 |
2019-10-24 |
|
| Organic compositions to treat APOC3-related diseases |
2019-2-06 |
2021-7-20 |
2021-7-20 |
| Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo |
2018-11-13 |
2019-2-28 |
|
| Integrin ligands and uses thereof. |
2018-10-31 |
2022-10-27 |
|
| RNAi agents and compositions for inhibiting expression of Asialoglycoprotein … |
2018-10-17 |
2019-5-16 |
|
| IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF … |
2018-10-17 |
2020-5-06 |
|
| RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions |
2018-10-11 |
2019-1-31 |
|
| IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 ( … |
2018-9-14 |
2020-3-11 |
|
| Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 ( … |
2018-9-13 |
2020-4-18 |
|
| RNAI agents and compositions for inhibiting expression of Angiopoietin-like 3 ( … |
2018-9-13 |
2020-11-13 |
|
| IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III … |
2018-9-11 |
2020-1-15 |
|
| RNAI agents and compositions for inhibiting expression of apolipoprotein C-lll … |
2018-9-10 |
2020-11-13 |
|
| Methods Of Treatment For Alpha-1 Antitrypsin Deficiency |
2018-8-09 |
2019-3-07 |
|
| Method of modifying a peptide |
2018-7-11 |
2018-11-01 |
|
| IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE |
2018-7-06 |
2019-12-11 |
|
| RNAi agents for inhibiting expression of alpha-ENaC and methods of use. |
2018-7-05 |
2020-10-23 |
|
| Organic compositions to treat beta-catenin-related diseases |
2018-6-13 |
2018-10-04 |
|
| Biologically Cleavable Tetrapeptide Linking Agents |
2018-5-25 |
2018-9-13 |
|
| IRNA A-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING iRNA AAT AGENTS AND … |
2018-1-10 |
2019-5-02 |
|
| Disulfide-containing alkyne linking agents |
2017-9-27 |
2018-8-14 |
2018-8-14 |
| RNAi agents for hepatitis B virus infection. |
2017-8-04 |
2020-10-23 |
|
| RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION |
2017-8-04 |
2022-8-26 |
|
| IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS |
2017-8-04 |
2018-11-14 |
|
| RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION |
2017-8-04 |
2022-8-26 |
|
| RNAi agents for hepatitis B virus infection |
2017-8-04 |
2021-5-26 |
|
| Agents d'interference arn pour inhiber l'expression d'un recepteur pour des … |
2022-4-07 |
2022-10-13 |
|
| Agentes de rnai para a infecção pelo vírus da hepatite b |
2020-2-07 |
2021-10-05 |
|